{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:27:55Z","timestamp":1761593275378,"version":"build-2065373602"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rdc.2025.07.006","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:45:59Z","timestamp":1757501159000},"page":"609-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Treatment Options for Inclusion Body Myositis"],"prefix":"10.1016","volume":"51","author":[{"given":"James B.","family":"Lilleker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefen","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.rdc.2025.07.006_bib1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.43.5.876","article-title":"Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin","volume":"43","author":"Soueidan","year":"1993","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.006_bib2","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1212\/WNL.44.8.1516","article-title":"Inclusion body myositis: treatment with intravenous immunoglobulin","volume":"44","author":"Amato","year":"1994","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.006_bib3","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.006_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.006_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.006_bib6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00005792-199307000-00002","article-title":"The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy","volume":"72","author":"Leff","year":"1993","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.006_bib7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","article-title":"Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study","volume":"61","author":"Lindberg","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.006_bib8","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","article-title":"Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis","volume":"57","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.006_bib9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","article-title":"Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis","volume":"63","year":"2004","journal-title":"Neurology"},{"issue":"2 Suppl 1","key":"10.1016\/j.rdc.2025.07.006_bib10","first-page":"S123","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.rdc.2025.07.006_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","article-title":"The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study","volume":"334","author":"Kosmidis","year":"2013","journal-title":"J Neurol Sci"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.006_bib12","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"Pt 6","key":"10.1016\/j.rdc.2025.07.006_bib13","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.006_bib14","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.006_bib15","first-page":"316","article-title":"Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM functional rating scale","volume":"43","author":"Badrising","year":"2025","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.006_bib16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","article-title":"A pilot randomized trial of oxandrolone in inclusion body myositis","volume":"58","author":"Rutkove","year":"2002","journal-title":"Neurology"},{"issue":"331","key":"10.1016\/j.rdc.2025.07.006_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad4583","article-title":"Targeting protein homeostasis in sporadic inclusion body myositis","volume":"8","author":"Ahmed","year":"2016","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.rdc.2025.07.006_bib18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S1474-4422(23)00275-2","article-title":"Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Machado","year":"2023","journal-title":"Lancet Neurol"},{"issue":"24","key":"10.1016\/j.rdc.2025.07.006_bib19","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.006_bib20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol"},{"issue":"14","key":"10.1016\/j.rdc.2025.07.006_bib21","doi-asserted-by":"crossref","first-page":"e1971","DOI":"10.1212\/WNL.0000000000010417","article-title":"Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis","volume":"95","author":"Sivakumar","year":"2020","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.006_bib22","doi-asserted-by":"crossref","first-page":"e1595","DOI":"10.1212\/WNL.0000000000011626","article-title":"Efficacy and safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT","volume":"96","author":"Amato","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.006_bib23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","article-title":"Follistatin gene therapy for sporadic inclusion body Myositis improves functional outcomes","volume":"25","author":"Mendell","year":"2017","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.006_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2217\/cpr.14.54","article-title":"Inclusion body myositis: clinical review and current practice","volume":"11","author":"Brady","year":"2014","journal-title":"Clin Pract"},{"issue":"Issue 11","key":"10.1016\/j.rdc.2025.07.006_bib25","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.rdc.2025.07.006_bib26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nmd.2013.02.010","article-title":"Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials","volume":"23","author":"Cortese","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.006_bib27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.rdc.2025.07.006_bib28","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2013-305690","article-title":"Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features","volume":"84","author":"Brady","year":"2013","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"20","key":"10.1016\/j.rdc.2025.07.006_bib29","doi-asserted-by":"crossref","first-page":"e2212","DOI":"10.1212\/WNL.0000000000201103","article-title":"Morphologic and molecular patterns of polymyositis with mitochondrial pathology and inclusion body myositis","volume":"99","author":"Kleefeld","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.rdc.2025.07.006_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.rdc.2025.07.006_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.nmd.2010.03.014","article-title":"International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009","volume":"20","author":"Benveniste","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.rdc.2025.07.006_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","article-title":"272nd ENMC international workshop: 10 years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, the Netherlands","volume":"37","author":"Lilleker","year":"2024","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.006_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/mus.20958","article-title":"Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity","volume":"37","author":"Jackson","year":"2008","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.006_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/jnnp-2024-333617","article-title":"Measurement properties of the inclusion body myositis functional rating scale","volume":"96","author":"Salam","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.006_bib35","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/mus.25079","article-title":"Development of the sporadic inclusion body myositis physical functioning assessment","volume":"54","author":"DeMuro","year":"2016","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.006_bib36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/mus.26521","article-title":"Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis","volume":"60","author":"Ramdharry","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.rdc.2025.07.006_bib37","doi-asserted-by":"crossref","unstructured":"Rosero S, Seabury J, Bhagchandani P, et al. The inclusion body myositis-health index (IBM-HI): development and validation of a novel, disease-specific, patient-reported outcome measure. J Neurological Sci 2023;455:122033. Abstract. Available at: https:\/\/www.jns-journal.com\/article\/S0022-510X(23)01494-6\/fulltext.","DOI":"10.1016\/j.jns.2023.122033"},{"key":"10.1016\/j.rdc.2025.07.006_bib38","article-title":"Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis","volume":"13","author":"Sangha","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.006_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.reuma.2021.01.007","article-title":"Myo-Spain: Spanish Registry of patients with idiopathic inflammatory myopathy. Methodology","volume":"18","author":"Cobo-Ib\u00e1\u00f1ez","year":"2022","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.006_bib40","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1093\/brain\/awz207","article-title":"Highly differentiated cytotoxic T cells in inclusion body myositis","volume":"142","author":"Greenberg","year":"2019","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.006_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0283394","article-title":"Testosterone treatment combined with exercise to improve muscle strength, physical function and quality of life in men affected by inclusion body myositis: a randomised, double-blind, placebo-controlled, crossover trial","volume":"18","author":"Connor","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.rdc.2025.07.006_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.nmd.2024.02.002","article-title":"Does inspiratory muscle training improve lung function and quality of life in people with inclusion body myositis? A pilot study","volume":"37","author":"Williams","year":"2024","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.006_bib43","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/03009742.2017.1423109","article-title":"Blood-flow restricted resistance training in patients with sporadic inclusion body myositis: a randomized controlled trial","volume":"47","author":"J\u00f8rgensen","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.006_bib44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/sms.14079","article-title":"Effects of blood-flow restricted resistance training on mechanical muscle function and thigh lean mass in sIBM patients","volume":"32","author":"J\u00f8rgensen","year":"2022","journal-title":"Scand J Med Sci Sports"},{"issue":"15","key":"10.1016\/j.rdc.2025.07.006_bib45","doi-asserted-by":"crossref","first-page":"e1773","DOI":"10.1212\/WNL.0000000000007265","article-title":"Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity","volume":"92","author":"Wallace","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.rdc.2025.07.006_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jocn.2020.09.031","article-title":"Hybrid assistive limb\u00ae for sporadic inclusion body myositis: a case series","volume":"81","author":"Suzuki","year":"2020","journal-title":"J Clin Neurosci"},{"issue":"16","key":"10.1016\/j.rdc.2025.07.006_bib47","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1212\/WNL.0000000000006365","article-title":"Dermoskeletics to preserve mobility and function in inclusion body myositis","volume":"91","author":"Landon-Cardinal","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.006_bib48","article-title":"Tendon transfers to improve grip and pinch in patients with sporadic inclusion body myositis","volume":"11","author":"Hua","year":"2023","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.006_bib49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.nmd.2020.02.010","article-title":"Exploring the efficacy of the expiratory muscle strength trainer to improve swallowing in inclusion body myositis: a pilot study","volume":"30","author":"Mohannak","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.006_bib50","doi-asserted-by":"crossref","first-page":"E2426","DOI":"10.1002\/lary.29444","article-title":"Cricopharyngeal myotomy in inclusion body myositis: Comparison of endoscopic and transcervical approaches","volume":"131","author":"McMillan","year":"2021","journal-title":"Laryngoscope"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.006_bib51","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1007\/s00415-022-11028-8","article-title":"Botulinum toxin treatment improves dysphagia in patients with oculopharyngeal muscular dystrophy and sporadic inclusion body myositis","volume":"269","author":"Witting","year":"2022","journal-title":"J Neurol"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.006_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103644","article-title":"Inclusion body myositis: correcting impaired mitochondrial and lysosomal autophagy as a potential therapeutic strategy","volume":"23","author":"Brady","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.006_bib53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/JND-150138","article-title":"Mortality and causes of death in patients with sporadic inclusion body myositis: survey study based on the clinical experience of specialists in Australia, Europe and the USA","volume":"3","author":"Price","year":"2016","journal-title":"J Neuromuscul Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:23:21Z","timestamp":1761593001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0889857X25000535"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.006","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Treatment Options for Inclusion Body Myositis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}